Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio ViewXTAE:BIOV +0.12%41 FCF Margin % is 1.73% as of Dec. 2025, which is 147% above its 10-year median of 0.70. GuruFocus rates XTAE:BIOV with a GF Score™ of 41/100 and a GF Value™ of ₪1.71 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Bio View ranks worse than 68.88% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bio View's Free Cash Flow for the
six
months ended in Dec. 2025 was ₪0.18 Mil. Bio View's Revenue for the
six
months ended in Dec. 2025 was ₪10.66 Mil. Therefore, Bio View's FCF Margin % for the quarter that ended in Dec. 2025 was 1.73%.
The historical rank and industry rank for Bio View's FCF Margin % or its related term are showing as below:
XTAE:BIOV'
s FCF Margin % Range Over the Past 10 Years
Min: -15.6 Med: 0.7 Max: 10.84
Current: -15.6
During the past 13 years, the highest FCF Margin % of Bio View was 10.84%. The lowest was -15.60%. And the median was 0.70%.
XTAE:BIOV's FCF Margin % is ranked worse than 68.88% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: -0.56
vs XTAE:BIOV: -15.60
The historical data trend for Bio View's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:BIOV vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Bio View's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio View FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio View's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bio View's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio View (XTAE:BIOV) has a FCF Margin % of 1.73% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bio View and its competitors. This is 147% above median its historical median of 0.70. According to the industry distribution chart, Bio View ranks #560 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 68.9%.
Is Bio View's FCF Margin % too high?
Bio View's current FCF Margin % of 1.73% is 147% above median its 10-year median of 0.70. Based on the distribution chart, Bio View ranks #560 out of 813 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio View has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio View's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bio View ranks #560 out of 813 companies for FCF Margin %. This places Bio View in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bio View and its competitors. Bio View's current FCF Margin % is 1.73%, which is 147% above median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio View stock overvalued right now?
Based on GuruFocus' analysis, Bio View (XTAE:BIOV) is currently considered Possible Value Trap. The stock's GF Value™ is ₪1.71, compared to a current price of ₪0.82 — trading 52.3% below its estimated fair value. The current FCF Margin % is 1.73%, which is 147% above median its 10-year median of 0.70. Bio View's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bio View (XTAE:BIOV), the current FCF Margin % is 1.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio View (XTAE:BIOV) Overvalued in 2026?
Based on GuruFocus' analysis, Bio View stock appears to be undervalued.
The current stock price of ₪0.82 is trading 52.3% below its estimated GF Value™ of ₪1.71.
GuruFocus considers Bio View to be Possible Value Trap.
Key valuation signals for XTAE:BIOV:
FCF Margin %: 1.73% (147% above median its 10-year median of 0.70)
GF Value™: ₪1.71 vs. price of ₪0.82 (52.3% below fair value)
No single metric tells the full story. See the XTAE:BIOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
41GF Score
Get the complete analysis for XTAE:BIOV
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:BIOV has been successfully added to your 
